Dakuzhu Diankang

Daclizumab is an anti-CD25 monoclonal antibody used as an induction-immunosuppression option in kidney transplantation. In HCV-infected recipients, its significance lies not in a simple benefit or hazard but in the tension between reducing rejection-related treatment and potentially influencing the course of HCV-associated liver disease. The evidence remains mixed, and the book therefore places its use within individualized immunosuppressive decision-making rather than presenting it as a universally preferred drug.

Role in Induction Immunosuppression

Daclizumab belongs to the group of non-depleting induction antibodies considered for kidney transplant recipients. Induction therapy itself is not regarded as categorically contraindicated in HCV-infected patients. A short course may reduce acute rejection and thereby lessen the need for high-dose steroid treatment, although the choice of induction agent must be adapted to the recipient’s overall immunological risk and comorbidities rather than to HCV status alone.

The evidence summarized for HCV-infected kidney recipients does not establish a consistent effect on viral activity. In a retrospective review of 104 recipients, induction with antithymocyte globulin produced HCV viral loads similar to those observed without induction, and other outcomes were also similar according to the induction strategy. In a separate long-term single-center study involving 110 HCV-infected recipients and pretransplant and posttransplant liver biopsies, however, a subset of 31 recipients who received daclizumab showed worse progression of liver-fibrosis scores than recipients given antilymphocyte globulins.

Conflicting Comparative Evidence

The uncertainty surrounding daclizumab is reinforced by evidence from liver transplantation. One randomized controlled trial found no difference in HCV recurrence between recipients receiving daclizumab and those receiving thymoglobulin. Another randomized trial, involving 64 HCV-infected liver transplant recipients, found no differences in transaminase levels, HCV viral load, liver-fibrosis scores, or inflammation scores between patients receiving antithymocyte globulin and those receiving steroids as induction therapy. These findings suggest that a short course of antibody induction may not necessarily worsen HCV-related disease.

At the same time, registry evidence has pointed in different directions. One analysis of the United Network for Organ Sharing database reported inferior graft survival among HCV-infected liver transplant recipients who received antithymocyte globulin and steroids compared with those who received daclizumab. That result was not confirmed by another analysis of the same registry, in which induction therapy was associated with better patient and graft survival in recipients treated with either antithymocyte globulin or daclizumab. The contrast between these studies prevents a definitive ranking of daclizumab and competing induction regimens.

Position in Treatment Decisions

The broader immunosuppressive strategy for HCV-infected kidney transplant recipients was considered controversial, with insufficient evidence in 2011 to support an evidence-based regimen centered on one particular drug. No clear advantage was established for anti-IL-2 receptor monoclonal antibodies over antithymocyte globulins. Daclizumab therefore had to be weighed against the patient’s rejection risk, other illnesses, and the consequences of additional anti-rejection treatment, rather than selected solely because it was non-depleting.

The book distinguishes daclizumab from OKT3. OKT3, a depleting monoclonal antibody against CD3-positive cells, was associated with severe recurrent hepatitis C in liver transplant recipients and was considered a poor choice for induction or rejection treatment in HCV-infected recipients. Daclizumab did not carry that same categorical prohibition in the discussion, but its reported association with worse fibrosis progression meant that caution and clinical individualization remained necessary.

Clinical Significance

The debate over daclizumab illustrates the difficulty of managing HCV in the setting of transplantation. Immunosuppression can influence viral and hepatic outcomes, yet excessive avoidance of induction may increase acute rejection and expose the graft to high-dose steroid boluses or other rescue therapy. Conversely, an induction regimen that appears acceptable from the standpoint of rejection may still be viewed differently when serial liver biopsies show accelerated fibrosis.

The overall recommendation emerging from the evidence is restrained: if induction therapy is used in an HCV-infected recipient, a short course may be preferable, but available studies do not justify treating daclizumab as uniformly superior or uniformly harmful. Its place is consequently defined by competing risks, incomplete comparative evidence, and the need to preserve both graft function and long-term control of HCV-related liver disease.